記事
IX．甲状腺がんにおける抗がん薬治療
Digital data available（科学技術振興機構）
Begin reading now
J-STAGE
IX．甲状腺がんにおける抗がん薬治療
- Material type
- 記事
- Author
- 山﨑 知子
- Publisher
- The Japanese Society of Internal Medicine
- Publication date
- 2024-04-10
- Material Format
- Digital
- Journal name
- 日内会誌 113 4
- Publication Page
- p.668-675
Detailed bibliographic record
Summary, etc.：
- <p>甲状腺がんの薬物療法は，マルチキナーゼ阻害薬であるレンバチニブ，ソラフェニブ，バンデタニブ，およびRET阻害薬，NTRK阻害薬，BRAF阻害薬，免疫チェックポイント阻害薬などの臓器横断的な薬剤の承認で急激に進歩した．甲状腺がんでは治療につながりやすいActionableな遺伝子変異が多いとされ...
Holdings of Libraries in Japan
This page shows libraries in Japan other than the National Diet Library that hold the material.
Please contact your local library for information on how to use materials or whether it is possible to request materials from the holding libraries.
other
J-STAGE
DigitalCiNii Research
Search ServiceDigitalYou can check the holdings of institutions and databases with which CiNii Research is linked at the site of CiNii Research.
Bibliographic Record
You can check the details of this material, its authority (keywords that refer to materials on the same subject, author's name, etc.), etc.
Digital
- Material Type
- 記事
- Title
- Author Heading
- Publication Date
- 2024-04-10
- Publication Date (W3CDTF)
- 2024-04-10
- Periodical title
- 日内会誌
- No. or year of volume/issue
- 113 4
- Volume
- 113
- Issue
- 4
- Pages
- 668-675
- Publication date of volume/issue (W3CDTF)
- 2024-04-10
- ISSN (Periodical Title)
- 00215384
- Publication (Periodical Title)
- The Japanese Society of Internal Medicine
- Text Language Code
- ja
- Subject Heading
- Target Audience
- 一般
- DOI
- 10.2169/naika.113.668
- Related Material (URI)
- References
- State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent CancersCabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trialCombination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid CarcinomaClinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational studyDabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trialEfficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 studyPralsetinib in patients (pts) with advanced or metastatic <i>RET</i>-altered thyroid cancer (TC): Updated data from the ARROW trial.Cytotoxic Effects of Carboplatinum and Epirubicin in the Setting of an Elevated Serum Thyrotropin for Advanced Poorly Differentiated Thyroid CancerKIF5B-RET fusions in lung adenocarcinomaGenetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid CancersGenomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasisEfficacy of Selpercatinib in <i>RET</i> -Altered Thyroid CancersThe epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020Dabrafenib Versus Dabrafenib + Trametinib in <i>BRAF</i>-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter TrialPralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyTumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial1645O Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trialThe landscape of kinase fusions in cancerTRK inhibitors in TRK fusion-positive cancersMolecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know?Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted SequencingA phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialLong-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine TherapyBRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of ResistanceMolecular genetics and diagnosis of thyroid cancerSafety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancerPrognostic Factors and Treatment Outcomes for Anaplastic Thyroid Carcinoma: ATC Research Consortium of Japan Cohort Study of 677 PatientsPD-1 Blockade in Anaplastic Thyroid CarcinomaVandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialNTRK fusion-positive cancers and TRK inhibitor therapySalvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinomaLenvatinib versus Placebo in Radioiodine-Refractory Thyroid CancerChemotherapy of Thyroid Cancer with AdriamycinGenomic Characterization of Differentiated Thyroid CarcinomaSafety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 StudyLandscape of Microsatellite Instability Across 39 Cancer TypesA randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinomaCorrelation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas
- Data Provider (Database)
- 国立情報学研究所 : CiNii Research
- Original Data Provider (Database)
- Japan Link CenterCrossref